Zoetis Inc. $ZTS Shares Bought by Burling Wealth Partners LLC

Burling Wealth Partners LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 22.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 27,100 shares of the company’s stock after acquiring an additional 4,880 shares during the quarter. Burling Wealth Partners LLC’s holdings in Zoetis were worth $4,226,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Nova Wealth Management Inc. purchased a new stake in shares of Zoetis during the first quarter worth approximately $25,000. 1248 Management LLC purchased a new position in Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank acquired a new stake in Zoetis during the first quarter worth approximately $29,000. REAP Financial Group LLC boosted its holdings in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC grew its position in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after buying an additional 85 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. UBS Group dropped their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Morgan Stanley cut their price target on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday. Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Argus reissued a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $180.00.

Zoetis Stock Performance

NYSE:ZTS opened at $121.04 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market cap of $53.34 billion, a price-to-earnings ratio of 20.83, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The firm’s fifty day moving average price is $141.57 and its 200 day moving average price is $151.73. Zoetis Inc. has a 1-year low of $117.26 and a 1-year high of $181.85.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the business earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is currently 33.67%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.